ZBH ZIMMER BIOMET HOLDINGS, INC.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1136869 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.0%
TTM net income YoY-4.7%
TTM EPS YoY-1.7%
Revenue 3-yr CAGR5.6%
Net income 3-yr CAGR17.4%
Margins
Gross margin69.7%
Operating margin13.6%
Net margin9.0%
FCF margin19.2%
EBITDA margin26.5%
Returns
ROE6.0%
ROA3.3%
ROIC (approx.)5.1%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets45.9%
Debt / equity0.59x
Current ratio1.46x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.46x
Accruals ratio-4.8%
Payout ratio24.3%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.06B | $2.18B | $2.09B | $2.24B | $2.00B | $2.08B | $1.91B | $2.02B |
| Cost of revenue | $594.50M | $635.50M | $576.20M | $792.40M | $559.30M | $592.20M | $549.80M | $586.70M |
| Gross profit | $1.47B | $1.54B | $1.51B | $1.45B | $1.44B | $1.49B | $1.36B | $1.44B |
| R&D expense | $105.90M | $104.80M | $103.40M | $118.70M | $115.90M | $113.30M | $110.60M | $108.50M |
| SG&A expense | $855.00M | $899.30M | $849.90M | $872.30M | $811.40M | $814.80M | $758.80M | $746.90M |
| Operating income | $307.60M | $326.10M | $373.20M | $154.50M | $351.30M | $300.00M | $292.30M | $389.00M |
| Pretax income | $230.10M | $255.10M | $301.30M | $98.00M | $279.20M | $224.60M | $229.00M | $289.00M |
| Income tax | $37.20M | $55.50M | $63.00M | -$39.90M | $48.00M | $71.20M | $46.50M | $48.90M |
| Net income | $191.60M | $198.30M | $238.10M | $139.30M | $230.90M | $152.80M | $182.00M | $239.50M |
| EBITDA | $589.60M | $596.90M | $643.20M | $438.50M | $634.90M | $571.80M | $546.70M | $652.60M |
| EPS (basic) | 1.01 | 1.03 | 1.22 | — | 1.17 | 0.77 | 0.92 | — |
| EPS (diluted) | 1.00 | 1.03 | 1.22 | — | 1.16 | 0.77 | 0.91 | — |
| Dividends declared per share | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
| Weighted avg. shares (diluted) | 191.40M | 192.80M | 195.80M | — | 198.80M | 198.30M | 199.70M | — |
| Banking | ||||||||
| Net interest income | -$74.90M | -$72.90M | -$68.80M | -$71.90M | -$75.40M | -$79.30M | -$66.20M | -$61.90M |
| Balance sheet | ||||||||
| Cash & equivalents | $399.90M | $410.00M | $424.20M | $591.90M | $1.29B | $556.90M | $1.38B | $525.50M |
| Receivables | $1.82B | $1.77B | $1.73B | $1.70B | $1.60B | $1.61B | $1.53B | $1.48B |
| Inventory | $2.37B | $2.27B | $2.25B | $2.29B | $2.48B | $2.45B | $2.24B | $2.24B |
| Current assets | $5.13B | $5.10B | $4.96B | $5.12B | $5.83B | $5.05B | $5.59B | $4.67B |
| PP&E, net | $2.31B | $2.24B | $2.21B | $2.21B | $2.19B | $2.18B | $2.06B | $2.05B |
| Goodwill | $10.34B | $9.92B | $9.93B | $9.95B | $9.70B | $9.71B | $8.99B | $8.95B |
| Intangibles | $4.63B | $4.46B | $4.55B | $4.72B | $4.74B | $4.89B | $4.47B | $4.60B |
| Total assets | $23.54B | $22.80B | $22.72B | $23.09B | $23.49B | $22.87B | $22.18B | $21.37B |
| Current liabilities | $3.50B | $3.01B | $2.86B | $2.58B | $2.40B | $2.70B | $2.29B | $2.45B |
| Short-term debt | $1.29B | $1.20B | $1.18B | $587.10M | $600.00M | $820.00M | $600.00M | $863.00M |
| Long-term debt | $6.22B | $6.28B | $6.30B | $6.93B | $7.51B | $6.75B | $6.58B | $5.34B |
| Total debt | $7.50B | $7.48B | $7.47B | $7.52B | $8.11B | $7.57B | $7.18B | $6.20B |
| Total liabilities | $10.81B | $10.17B | $10.04B | $10.39B | $10.72B | $10.33B | $9.78B | $8.89B |
| Shareholders' equity | $12.72B | $12.62B | $12.67B | $12.70B | $12.76B | $12.53B | $12.40B | $12.47B |
| Net debt | $7.10B | $7.07B | $7.05B | $6.93B | $6.82B | $7.02B | $5.79B | $5.68B |
| Cash flow statement | ||||||||
| Operating cash flow | $560.00M | $447.80M | $359.40M | $517.40M | $418.70M | $378.20M | $382.80M | $506.30M |
| Capital expenditure | $75.80M | $54.20M | $36.30M | $74.80M | $55.00M | $50.10M | $44.60M | $51.50M |
| Free cash flow | $484.20M | $393.60M | $323.10M | $442.60M | $363.70M | $328.10M | $338.20M | $454.80M |
| Investing cash flow | -$543.30M | -$190.80M | -$159.00M | -$322.00M | -$163.30M | -$1.38B | -$106.00M | -$291.20M |
| Financing cash flow | -$27.20M | -$271.10M | -$369.20M | -$897.00M | $483.80M | $163.80M | $575.40M | -$240.60M |
| Depreciation & amortization | $282.00M | $270.80M | $270.00M | $284.00M | $283.60M | $271.80M | $254.40M | $263.60M |
| Stock-based compensation | $24.20M | $24.60M | $24.20M | $24.10M | $25.30M | $21.20M | $19.60M | $21.10M |
| Dividends paid | $45.80M | $46.50M | $46.90M | $47.50M | $47.50M | $47.50M | $47.80M | $48.00M |
| Share buybacks | $78.50M | $250.70M | $250.10M | $250.00M | $0 | $7.20M | $229.80M | $72.20M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.